Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00073723 | Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 75 | Celgene CorporationINDUSTRY | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00874848 | Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | HiberCell, Inc.INDUSTRY | 2 | Nov 29, 2016 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00124280 | Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 85 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01070927 | An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00753714 | Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine(ZELIG) | completed | Phase 2 | 124 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00777179 | Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy | completed | Phase 2 | 117 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00741195 | Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 50 | Hellenic Oncology Research GroupOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00741221 | Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer | completed | Phase 2 | 50 | Hellenic Oncology Research GroupOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00753909 | Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 50 | Hellenic Oncology Research GroupOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00755170 | Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer | completed | Phase 2 | 48 | Hellenic Oncology Research GroupOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00216203 | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Nasser Hanna, M.D.OTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01496742 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 259 | Genentech, Inc.INDUSTRY | 13 | Sep 23, 2016 | clinicaltrials |
| NCT00824408 | Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC | completed | Phase 2 | 143 | Boehringer IngelheimINDUSTRY | 2 | Sep 20, 2016 | clinicaltrials |
| NCT00525148 | LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations | completed | Phase 2 | 129 | Boehringer IngelheimINDUSTRY | 2 | Sep 16, 2016 | clinicaltrials |
| NCT00323869 | Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer | completed | Phase 2 | 48 | Stanford UniversityOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01519804 | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 108 | Genentech, Inc.INDUSTRY | 9 | Sep 2, 2016 | clinicaltrials |
| NCT01221675 | TF2- Small Cell Lung Cancer Radio Immunotherapy | completed | Phase 1 / Phase 2 | 18 | Centre René GauducheauOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00047840 | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | completed | Phase 2 | 129 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Aug 25, 2016 | clinicaltrials |
| NCT00071188 | ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 9 | Aug 25, 2016 | clinicaltrials |
| NCT00252746 | ZD6474 Phase IIa Dose Finding Multicentre Study | completed | Phase 2 | 53 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00059722 | This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | completed | Phase 2 | 160 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Aug 24, 2016 | clinicaltrials |
| NCT00994123 | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 162 | Merrimack PharmaceuticalsINDUSTRY | 6 | Aug 22, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT02774278 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)(MERIT) | completed | Phase 2 | 264 | Hoffmann-La RocheINDUSTRY | 14 | Aug 8, 2016 | clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT00826449 | Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT01788566 | A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer | completed | Phase 2 | 61 | Eli Lilly and CompanyINDUSTRY | 7 | Jun 27, 2016 | clinicaltrials |
| NCT01194453 | Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer(AP/GP) | completed | Phase 2 | 288 | Sun Yat-sen UniversityOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT00508625 | A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | completed | Phase 2 | 213 | AmgenINDUSTRY | 0 | Jun 14, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT00259064 | Iressa v BSC (Best Supportive Care) in First Line NSCLC(INSTEP) | completed | Phase 2 / Phase 3 | 216 | AstraZenecaINDUSTRY | 5 | Jun 2, 2016 | clinicaltrials |
| NCT00642473 | A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash(MATER) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 1 | May 23, 2016 | clinicaltrials |
| NCT01047059 | Molecular Imaging With Erlotinib and Bevacizumab(MIMEB) | completed | Phase 2 | 40 | University of CologneOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT00651508 | Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 1 | May 17, 2016 | clinicaltrials |
| NCT00518011 | A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer. | completed | Phase 2 | 17 | Hoffmann-La RocheINDUSTRY | 1 | May 16, 2016 | clinicaltrials |
| NCT01291017 | Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. | completed | Phase 2 | 19 | University of FloridaOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT01042288 | Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC | completed | Phase 2 | 70 | SCRI Development Innovations, LLCOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01076504 | A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 81 | SCRI Development Innovations, LLCOTHER | 1 | May 5, 2016 | clinicaltrials |
| NCT01792479 | A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 64 | BIND TherapeuticsINDUSTRY | 2 | Apr 15, 2016 | clinicaltrials |
| NCT01331525 | The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer(ICE) | completed | Phase 2 | 42 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00609804 | Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | completed | Phase 2 | 53 | SCRI Development Innovations, LLCOTHER | 1 | Apr 8, 2016 | clinicaltrials |
| NCT02720614 | Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 12 | LIN QIANGOTHER | 0 | Mar 28, 2016 | clinicaltrials |
| NCT00094835 | Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 51 | AmgenINDUSTRY | 0 | Mar 24, 2016 | clinicaltrials |
| NCT00888823 | Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 13 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT00198432 | Chemoradiotherapy of NSCLC Stage IIIB | completed | Phase 2 | 130 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00930891 | Bevacizumab in Extensive Small Cell Lung Cancer(CPC) | completed | Phase 2 / Phase 3 | 143 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 10, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2016source: clinicaltrials